{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:03:54Z","timestamp":1790597034107,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03079"],"award-info":[{"award-number":["21H03079"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K16822"],"award-info":[{"award-number":["21K16822"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10147-022-02212-x","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T02:02:22Z","timestamp":1657850542000},"page":"1644-1650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-0820","authenticated-orcid":false,"given":"Tomoko","family":"Yoshihama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8214-2242","authenticated-orcid":false,"given":"Tatsuyuki","family":"Chiyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-6121","authenticated-orcid":false,"given":"Mio","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-1692","authenticated-orcid":false,"given":"Takuma","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5619-5148","authenticated-orcid":false,"given":"Keiko","family":"Saotome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4039-7212","authenticated-orcid":false,"given":"Yoshiko","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-086X","authenticated-orcid":false,"given":"Kensuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-2845","authenticated-orcid":false,"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3925-6057","authenticated-orcid":false,"given":"Wataru","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-8326","authenticated-orcid":false,"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"2212_CR1","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"JA Ledermann","year":"2012","unstructured":"Ledermann JA, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1105535","journal-title":"N Engl J Med"},{"key":"2212_CR2","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274\u20131284. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2","journal-title":"Lancet Oncol"},{"issue":"6","key":"2212_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/ijgc-2019-000384","volume":"29","author":"T Enomoto","year":"2019","unstructured":"Enomoto T, Aoki D, Hattori K et al (2019) The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectional approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer 29(6):1043\u20131049. https:\/\/doi.org\/10.1136\/ijgc-2019-000384","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"2212_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41523-020-0163-1","volume":"12","author":"T Kaneyasu","year":"2020","unstructured":"Kaneyasu T, Mori S, Yamauchi H et al (2020) Prevalence of disease-causing genes in Japanese patients with BRCA1\/2-wildtype hereditary breast and ovarian cancer syndrome. NPJ Breast Cancer 12(6):25. https:\/\/doi.org\/10.1038\/s41523-020-0163-1","journal-title":"NPJ Breast Cancer"},{"key":"2212_CR5","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 23:2605\u20132612. https:\/\/doi.org\/10.1093\/annonc\/mds203","journal-title":"Ann Oncol"},{"key":"2212_CR6","first-page":"1457","volume":"47","author":"T Takei","year":"2020","unstructured":"Takei T, Takaki E, Tsuji S et al (2020) Efficacy of olaparib treatment for platinum-sensitive recurrent ovarian, Fallopian tube, and primary peritoneal cancers. Gan To Kagaku Ryoho 47:1457\u20131460","journal-title":"Gan To Kagaku Ryoho"},{"key":"2212_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","volume":"11","author":"J Mateo","year":"2016","unstructured":"Mateo J, Moreno V, Gupta A et al (2016) An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol 11:401\u2013415. https:\/\/doi.org\/10.1007\/s11523-016-0435-8","journal-title":"Target Oncol"},{"key":"2212_CR8","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.clinthera.2016.08.010","volume":"38","author":"L Dirix","year":"2016","unstructured":"Dirix L, Swaisland H, Verheul HM et al (2016) Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: Results of two PhaseI open-label studies. Clin Ther 38:2286\u20132299. https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.010","journal-title":"Clin Ther"},{"key":"2212_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/00498254.2017.1346332","volume":"48","author":"A McCormick","year":"2018","unstructured":"McCormick A, Swaisland H, Reddy VP et al (2018) In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450. Xenobiotica 48:555\u2013564. https:\/\/doi.org\/10.1080\/00498254.2017.1346332","journal-title":"Xenobiotica"},{"key":"2212_CR10","unstructured":"https:\/\/www.snpedia.com\/index.php\/CYP3A5"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02212-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T02:05:16Z","timestamp":1664157916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02212-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02212-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daisuke Aoki reports grants and honoraria from Takeda Pharmaceutical Company; honoraria from MSD, AstraZeneca and Chugai Pharmaceutical Company. Yusuke Kobayashi reports grants and honoraria from Takeda Pharmaceutical Company. The other authors declare no conflict of interest regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}